Loading
The randomised test of an off-the-shelf KRAS vaccine after pancreatic surgery. It missed its primary goal in June 2026.
Did not meet the pre-specified primary DFS endpoint in the intent-to-treat population; post-hoc landmark analyses suggested ~14% absolute DFS benefit during active dosing. Company is exploring R0-resected subgroups for phase 3. A cautionary data point for shared-antigen vaccines versus personalised approaches.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
158 enrolled.
Primary endpoint not met (sponsor release, 15 June 2026); ITT hazard ratio and medians not disclosed.
SourcePost hoc analysis of 121 R0-resected patients; hypothesis-generating only.
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Disease-free survival (ITT)primary | ELI-002 7P | - | Primary endpoint not met (sponsor release, 15 June 2026); ITT hazard ratio and medians not disclosed. | - | - | link |
| Observation | - | - | ||||
| Disease-free survival at 3 months (landmark) | ELI-002 7P | - | 90.3% | - | 0.022 | link |
| Observation | - | 76.6% | ||||
| Disease-free survival, R0-resected subgroup (post hoc) | ELI-002 7P | - | 23.8 months | 0.65 | 0.048 | link |
| Observation | - | 12.8 months |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Autogene cevumeran phase 1 in resected pancreatic cancer (Memorial Sloan Kettering), Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, The undruggable drivers, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma.
Shares A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC, Autogene cevumeran phase 1 in resected pancreatic cancer (Memorial Sloan Kettering), Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question.
Shares Pancreatic cancer: the failed and stopped programmes and why, Resectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Off-the-shelf cancer vaccines, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Off-the-shelf cancer vaccines, Pancreatic ductal adenocarcinoma.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Resectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/